162 related articles for article (PubMed ID: 11908872)
1. Prognostic value of Ki-67 (MIB-1) and p53 in ependymomas.
Suzuki S; Oka H; Kawano N; Tanaka S; Utsuki S; Fujii K
Brain Tumor Pathol; 2001; 18(2):151-4. PubMed ID: 11908872
[TBL] [Abstract][Full Text] [Related]
2. Proliferation- and apoptosis-related proteins in intracranial ependymomas: an immunohistochemical analysis.
Verstegen MJ; Leenstra DT; Ijlst-Keizers H; Bosch DA
J Neurooncol; 2002 Jan; 56(1):21-8. PubMed ID: 11949823
[TBL] [Abstract][Full Text] [Related]
3. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
[TBL] [Abstract][Full Text] [Related]
4. Histological spectrum of ependymomas and correlation of p53 and Ki-67 expression with ependymoma grade and subtype.
Suri VS; Tatke M; Singh D; Sharma A
Indian J Cancer; 2004; 41(2):66-71. PubMed ID: 15318011
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry.
Prayson RA
Ann Diagn Pathol; 1999 Feb; 3(1):11-8. PubMed ID: 9990108
[TBL] [Abstract][Full Text] [Related]
6. Ependymomas: MIB-1 proliferation index and survival.
Ritter AM; Hess KR; McLendon RE; Langford LA
J Neurooncol; 1998 Oct; 40(1):51-7. PubMed ID: 9874186
[TBL] [Abstract][Full Text] [Related]
7. Correlation of p53 and KI-67 expression with grade and subtype of ependymoma.
Manasa LP; Uppin MS; Sundaram C
Indian J Pathol Microbiol; 2012; 55(3):308-13. PubMed ID: 23032822
[TBL] [Abstract][Full Text] [Related]
8. Cyclin D1 and MIB-1 immunohistochemistry in ependymomas: a study of 41 cases.
Prayson RA
Am J Clin Pathol; 1998 Nov; 110(5):629-34. PubMed ID: 9802348
[TBL] [Abstract][Full Text] [Related]
9. Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas.
Kurt E; Zheng PP; Hop WC; van der Weiden M; Bol M; van den Bent MJ; Avezaat CJ; Kros JM
Cancer; 2006 Jan; 106(2):388-95. PubMed ID: 16342252
[TBL] [Abstract][Full Text] [Related]
10. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors.
Zamecnik J; Snuderl M; Eckschlager T; Chanova M; Hladikova M; Tichy M; Kodet R
Mod Pathol; 2003 Oct; 16(10):980-91. PubMed ID: 14559980
[TBL] [Abstract][Full Text] [Related]
11. Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma.
Wolfsberger S; Fischer I; Höftberger R; Birner P; Slavc I; Dieckmann K; Czech T; Budka H; Hainfellner J
Am J Surg Pathol; 2004 Jul; 28(7):914-20. PubMed ID: 15223962
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature.
Reavey-Cantwell JF; Haroun RI; Zahurak M; Clatterbuck RE; Parker RJ; Mehta R; Fruehauf JP; Brem H
J Neurooncol; 2001 Dec; 55(3):195-204. PubMed ID: 11859975
[TBL] [Abstract][Full Text] [Related]
13. Expression of telomerase RNA component correlates with the MIB-1 proliferation index in ependymomas.
Rushing EJ; Yashima K; Brown DF; White CL; Shay JW; Risser RC; Gazdar AF
J Neuropathol Exp Neurol; 1997 Oct; 56(10):1142-6. PubMed ID: 9329458
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of histopathological ependymoma variants.
Neumann JE; Spohn M; Obrecht D; Mynarek M; Thomas C; Hasselblatt M; Dorostkar MM; Wefers AK; Frank S; Monoranu CM; Koch A; Witt H; Kool M; Pajtler KW; Rutkowski S; Glatzel M; Schüller U
Acta Neuropathol; 2020 Feb; 139(2):305-318. PubMed ID: 31679042
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical markers for prognosis of ependymal neoplasms.
Korshunov A; Golanov A; Timirgaz V
J Neurooncol; 2002 Jul; 58(3):255-70. PubMed ID: 12187959
[TBL] [Abstract][Full Text] [Related]
16. Prognostic marker analysis in pediatric intracranial ependymomas.
McLendon RE; Lipp E; Satterfield D; Ehinger M; Austin A; Fleming D; Perkinson K; Lefaivre M; Zagzag D; Wiener B; Gururangan S; Fuchs H; Friedman HS; Herndon JE; Healy P
J Neurooncol; 2015 Apr; 122(2):255-61. PubMed ID: 25563815
[TBL] [Abstract][Full Text] [Related]
17. Clear cells are associated with proliferative activity in ependymoma: a quantitative study.
Ishizawa K; Komori T; Aihara Y; Maruyama T; Okada Y; Ikuta S; Muragaki Y; Hirose T; Homma T; Sasaki A
Clin Neuropathol; 2012; 31(3):146-51. PubMed ID: 22551919
[TBL] [Abstract][Full Text] [Related]
18. A clinicopathologic study of 81 patients with ependymomas and proposal of diagnostic criteria for anaplastic ependymoma.
Ho DM; Hsu CY; Wong TT; Chiang H
J Neurooncol; 2001 Aug; 54(1):77-85. PubMed ID: 11763426
[TBL] [Abstract][Full Text] [Related]
19. Nestin expression identifies ependymoma patients with poor outcome.
Milde T; Hielscher T; Witt H; Kool M; Mack SC; Deubzer HE; Oehme I; Lodrini M; Benner A; Taylor MD; von Deimling A; Kulozik AE; Pfister SM; Witt O; Korshunov A
Brain Pathol; 2012 Nov; 22(6):848-60. PubMed ID: 22568867
[TBL] [Abstract][Full Text] [Related]
20. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas.
Jensen V; Sørensen FB; Bentzen SM; Ladekarl M; Nielsen OS; Keller J; Jensen OM
Histopathology; 1998 Jun; 32(6):536-46. PubMed ID: 9675593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]